File S1 - Vaccinating Women Previously Exposed to Human Papillomavirus: A Cost-Effectiveness Analysis of the Bivalent Vaccine

Model Description and Supplementary Results. Table S1, Parameter definitions. Table S2, Number of new partnerships per year stratified by age and risk group. Table S3, Population size and death rates stratified by age group. Table S4, Screening and treatment rates stratified by age group and neoplastic status. Table S5, Lesion specific progression and regression parameters. Table S6, Vaccination Coverage for each dose stratified by age. Table S7, Effect of altering discount rate on median incremental cost effectiveness ratio. Table S8, HPV type specific incidence and transmission probability. Figure S1, A Flow Diagram of the Model. Figure S2, The differential equations of the model. Figure S3, Model estimates of age specific prevalence of HPV-16 compared to trial data to which it was fitted. Figure S4, Cost effectiveness acceptability curves for extending the vaccination catch-up programme up to 24 year olds (assuming a lower coverage of the school based programme targeting 12-13 year olds). Figure S5, Cost effectiveness acceptability curves for extending the vaccination catch-up programme up to 24 year olds (assuming 75% vaccine efficacy for non-naive women). Figure S6, Cost effectiveness acceptability curves for extending the vaccination catch-up programme up to 24 year olds (assuming 50% vaccine efficacy for non-naive women).

(DOC)